Rituxan, one of Roche's King brand biological agents, was added with new indications to treat acquired thrombocytopenic purpura (attP)!

February 23, 2020 / BIOON / -- Chugai, a Japanese pharmaceutical company controlled by Roche, and zenyaku Kogyo) recently announced that Japan's Ministry of health, labor and welfare (MHLW) has approved rituxan (rituximab) 100mg and 500mg injection as a new indication for the treatment of acquired thrombocytopenic Pura (attP) Rituxian is jointly sold by two companies in Japan, and the two sides will continue to work closely together Thrombocytopenic purpura (TTP) is a serious disseminated thrombotic microangiopathy, characterized by hemolytic anemia of microangiopathy, decreased consumption of platelet aggregation, and organ damage (such as kidney, central nervous system, etc.) caused by microthrombosis The disease is caused by the decrease of the activity of a kind of macromolecular lyase, the depolymerizing protein like metalloproteinase (ADAMTS13) containing type I platelet binding protein motif, which promotes platelet aggregation In the past, TTP had a poor prognosis, a short course of disease, and a mortality rate of 80-90% without timely treatment With the clinical application of plasma exchange, the prognosis has greatly improved, and the mortality rate has dropped to 10-20% TTP can be divided into congenital TTP (cttp) caused by ADAMTS13 gene abnormality and acquired TTP (attP) caused by ADAMTS13 autoantibody In the treatment guidelines of Japan and other countries, rituxan has been listed as one of the treatment options for patients with failure or early recurrence of plasma exchange (attP first-line treatment) In Japan, TTP affects about 500 people every year, and the vast majority (95%) of them report it as attP Rituxan is a therapeutic monoclonal antibody that targets the CD20 antigen on the surface of normal and malignant B cells, then mobilizes the natural defense of human body, attacks and kills the labeled B cells Currently, in addition to various types of tumors, rituxan has been approved to treat various types of autoimmune diseases, including rheumatoid arthritis (RA), granulomatous polyangitis (GPA), microscopic polyangitis (MPA), pemphigus vulgaris (PV) At the end of September 2019, rituxan was approved by the U.S FDA and used in combination with glucocorticoids (GCC) for the treatment of GPA and MPa in children aged 2 and over It is worth mentioning that rituxan is the first and only FDA approved drug for the treatment of GPA and MPa in pediatric patients aged 2 years and over GPA and MPA are two rare and potentially life-threatening vasculitis that affect small and medium vessels The indication was approved through the FDA's priority review process and marks the first pediatric indication of rituxan GPA and MPA are two kinds of antineutrophil cytoplasmic antibody (ANCA) - associated vasculitis (AAV) AAV is a kind of vasculitis, which mainly affects small blood vessels In general, GPA and MPA affect small blood vessels in kidneys, lungs, sinuses and various other organs, but these diseases may have different effects on each patient Both GPA and MPA are considered rare diseases, with an estimated global prevalence of 23-160 cases per million people GPA and MPA cases in childhood are more rare and associated with severe, potentially life-threatening symptoms Original source: anti-CD20 monoclonal antibodiy "rituxan," app roved for additional indication of acquired fundamental tribocytopic purura